MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
zanubrutinib Sensitive: B - Late Trials
|
zanubrutinib Sensitive: B - Late Trials
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
MYD88 mutation
|
Marginal Zone Lymphoma
|
MYD88 mutation
|
Marginal Zone Lymphoma
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
MYD88 mutation
|
Diffuse Large B Cell Lymphoma
|
MYD88 mutation
|
Diffuse Large B Cell Lymphoma
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
MYD88 mutation
|
Diffuse Large B Cell Lymphoma
|
MYD88 mutation
|
Diffuse Large B Cell Lymphoma
|
methotrexate Sensitive: C3 – Early Trials
|
methotrexate Sensitive: C3 – Early Trials
|
MYD88 mutation
|
Marginal Zone Lymphoma
|
MYD88 mutation
|
Marginal Zone Lymphoma
|
zanubrutinib Sensitive: C3 – Early Trials
|
zanubrutinib Sensitive: C3 – Early Trials
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
rituximab Sensitive: C4 – Case Studies
|
rituximab Sensitive: C4 – Case Studies
|
MYD88 mutation
|
Diffuse Large B Cell Lymphoma
|
MYD88 mutation
|
Diffuse Large B Cell Lymphoma
|
BTK inhibitor + KT-413 Sensitive: D – Preclinical
|
BTK inhibitor + KT-413 Sensitive: D – Preclinical
|
MYD88 mutation
|
Diffuse Large B Cell Lymphoma
|
MYD88 mutation
|
Diffuse Large B Cell Lymphoma
|
rituximab + KT-413 Sensitive: D – Preclinical
|
rituximab + KT-413 Sensitive: D – Preclinical
|
MYD88 mutation
|
Diffuse Large B Cell Lymphoma
|
MYD88 mutation
|
Diffuse Large B Cell Lymphoma
|
KT-413 Sensitive: D – Preclinical
|
KT-413 Sensitive: D – Preclinical
|